RELATED STUDY
Ingestion of a THC-Rich Cannabis Oil in People with Fibromyalgia: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
Key Findings: The authors conclude that cannabis-based therapeutics can be a low-cost and well-tolerated therapeutic option to mitigate signs and symptoms of fibromyalgia as well as improve their quality of life.
Type of Study: Double Blind Clinical Trial
Study Sample Size: 17
Study Result: Positive
Study Location(s): Brazil
Year of Pub: 2020
Cannabinoids Studied: Cannabichromene (CBC), Cannabidiol (CBD), Cannabigerol (CBG), Tetrahydrocannabinol (THC), Cannabinol (CBN), Tetrahydrocannabivarin (THCV)
Phytocannabinoid Source: Cannabis Flower derived
Chemotype: Chemotype I
Terpenes Studied: ß-Caryophyllene, Myrcene, Pinene
DOSING DETAILS 
Study Dosing Objective: Effective Dose
Established Protocol: Effective dose
Route of Administration: Oral (Ingestion)
Cannabinoid Ratio: (THC : CBD) 61 : 1 
Dosage Form: White Widow variety, at a 24.44-mg/mL concentration of THC and 0.51 mg/mL of CBD—at a proportion of ∼48/1 THC/CBD
Dosing Regimen: Mean 3.6 drops a day (4.4 mg of THC and 0.08 mg of CBD)
Starting Dose: One drop (∼1.22 mg of THC and 0.02 mg of CBD) a day
Titration: Increases were titrated to effect
Treatment Duration: 8 weeks
Adverse Events: There was no follow-up loss by unpleasant adverse effects.
Additional Notes: Dose Titration
Link to study
